

Survey Says: A Grand Rounds Activity Focused on Key Management and Research Issues in Colorectal Cancer

Select Publications

Grothey

Benson AB 3rd, Hamilton SR. **Path toward prognostication and prediction: An evolving matrix.** *J Clin Oncol* 2011;29(35):4599-601.

Benson AB 3rd et al. **American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.** *J Clin Oncol* 2004;22(16):3408-19.

De Roock W et al. **Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.** *JAMA* 2010;304(16):1812-20.

Falcone A et al. **Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest.** *J Clin Oncol* 2007;25(13):1670-6.

Folprecht G et al. **Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial.** *Lancet Oncol* 2010;11(1):38-47.

Gerard JP et al. **Clinical results at 3 years of the ACCORD 12 randomized trial in rectal cancer.** Gastrointestinal Cancers Symposium 2012;Abstract 389.

Grothey A et al. **Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.** Gastrointestinal Cancers Symposium 2012;Abstract LBA385.

Grothey A et al. **Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE).** *J Clin Oncol* 2008;26(33):5326-34.

Nordlinger B et al. **Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial.** *Lancet* 2008;371(9617):1007-16.

Peeters M et al. **Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab).** Gastrointestinal Cancers Symposium 2012;Abstract 383.

Roh MS et al. **The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.** *Proc ASCO* 2011;Abstract 3503.

Tejpar S et al. **Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab.** *Proc ASCO* 2011;Abstract 3511.

Van Cutsem E et al. **Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): Results of a multinational phase 3 trial (EFC10262-VELOUR).** 13th ESMO World Congress on Gastrointestinal Cancer 2011;Abstract 0-0024.